Multi‐institutional, prospective, randomized, double‐blind, placebo‐controlled phase IIb trial of the tumor lysate, particle‐loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high‐risk melanoma patients: A subgroup analysis

Multi‐institutional, prospective, randomized, double‐blind, placebo‐controlled phase IIb trial of the tumor lysate, particle‐loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high‐risk melanoma patients: A subgroup analysis

Abstract Background Checkpoint inhibitors (CPI) in combination with cell‐based vaccines may produce synergistic antitumor immunity. The primary analysis of the randomized and blinded phase IIb trial in resected stage III/IV melanoma demonstrated TLPLDC is safe and improved 24‐month disease‐free surv...

Full description

Bibliographic Details
Main Authors: Robert C. Chick, Mark B. Faries, Diane F. Hale, Phillip M Kemp Bohan, Annelies T. Hickerson, Timothy J. Vreeland, John W. Myers III, Jessica L. Cindass, Tommy A. Brown II, John Hyngstrom, Adam C. Berger, James W. Jakub, Jeffrey J. Sussman, Montaser Shaheen, Guy T. Clifton, Hyohyun Park, Amanda J. Sloan, Thomas Wagner, George E. Peoples
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:Cancer Medicine
Subjects:
cancer vaccine
immunotherapy
melanoma
personalized medicine
Online Access:https://doi.org/10.1002/cam4.3969

Internet

https://doi.org/10.1002/cam4.3969

Similar Items